Regeneron Hits Profitability as Eylea Sales Blast Expectations
Regeneron Pharmaceuticals Inc.'s first-quarter earnings left consensus estimates in the dust, as higher-than-expected sales of age-related macular degeneration (AMD) drug Eylea (aflibercept ophthalmic solution) drove the company to profitability for the first time in its 24-year history.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter